CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- FinancialsAltman Z-Score 10.6: safe zone
- Interpretations4 currently firing — 4
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
670.25MUSDvs all stocks (USD)
Revenue (TTM)
38.46MUSDvs all stocks (USD)
Profit Margin
-115.12%vs Biotechnology peers
Beta
1.42xvs all stocks
52-Week Change
186.34%vs all stocks
Market Capitalization
670.25MUSDvs all stocks (USD)
Enterprise Value
637.17MUSDvs all stocks (USD)
Forward P/E
-15.63xvs Biotechnology peers
Price to Sales (TTM)
17.43xvs Biotechnology peers
Price to Book (MRQ)
2.58xvs Biotechnology peers
Enterprise to Revenue
16.57xvs Biotechnology peers
Enterprise to EBITDA
-29.50xvs Biotechnology peers
Gross Margin
95.45%vs Biotechnology peers
Profit Margin
-115.12%vs Biotechnology peers
Operating Margin
-49.47%vs Biotechnology peers
Return on Assets (TTM)
-8.35%vs Biotechnology peers
Return on Equity (TTM)
-16.95%vs Biotechnology peers
Revenue (TTM)
38.46MUSDvs all stocks (USD)
Revenue per Share (TTM)
0.3080USDUpdated Sep 28, 2026Quarterly Revenue Growth
244.20%vs Biotechnology peers
Gross Profit (TTM)
37.79MUSDvs all stocks (USD)
EBITDA (TTM)
-21.60MUSDvs all stocks (USD)
Net Income (TTM)
-44.27MUSDvs all stocks (USD)
Quarterly Earnings Growth (YoY)
244.24%vs Biotechnology peers
Operating Cash Flow (TTM)
-17.67MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-285.00KUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Sep 28, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
18.67MUSDFY2025 · Dec 31, 2025Cost of Goods Sold
303.00KUSDFY2025 · Dec 31, 2025Gross Profit
18.36MUSDFY2025 · Dec 31, 2025Operating Income
-68.97MUSDvs all stocks (USD)
Pre-tax Income
-66.29MUSDFY2025 · Dec 31, 2025Income Tax Expense
-1.51MUSDFY2025 · Dec 31, 2025Net Income
-64.78MUSDFY2025 · Dec 31, 2025EBIT
-68.97MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-47.22MUSDFY2025 · Dec 31, 2025Research & Development
47.75MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
29.21MUSDFY2025 · Dec 31, 2025Other Operating Expenses
-2.55MUSDFY2025 · Dec 31, 2025Non-operating Interest Income
2.66MUSDFY2025 · Dec 31, 2025EPS (Basic)
-0.5700USDFY2025 · Dec 31, 2025EPS (Diluted)
-0.5700USDFY2025 · Dec 31, 2025Basic Shares Outstanding
113.64MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
113.64MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-64.78MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-31.49MUSDFY2025 · Dec 31, 2025Free Cash Flow
-32.05MUSDDerived from operating cash flow minus capital expenditure. This filing charges 21.75M of depreciation against 565K of capital expenditure, and its own free-cash-flow line reads -37.02M.FY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
26.08MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-64.78MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
21.75MUSDFY2025 · Dec 31, 2025Deferred Taxes (CF)
-1.53MUSDFY2025 · Dec 31, 2025Stock-based Compensation
15.82MUSDFY2025 · Dec 31, 2025Other Non-cash Items
1.09MUSDFY2025 · Dec 31, 2025Change in Accounts Receivable (CF)
189.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
-231.00KUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
-3.80MUSDFY2025 · Dec 31, 2025Capital Expenditures
-565.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-46.86MUSDFY2025 · Dec 31, 2025Sale of Investments
50.89MUSDFY2025 · Dec 31, 2025Other Investing Activity
3.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
6.47MUSDFY2025 · Dec 31, 2025Other Financing Charges
-774.00KUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
27.43MUSDFY2025 · Dec 31, 2025Shares Outstanding
145.39MSharesUpdated Sep 28, 2026Float Shares
118.24MSharesUpdated Sep 28, 2026Shares Short
7.13MSharesUpdated Sep 28, 2026Short Ratio
2.73daysvs all stocks
Short % of Shares Outstanding
5.38%vs all stocks
% Held by Insiders
15.28%vs all stocks
% Held by Institutions
52.80%vs all stocks
Total Cash (MRQ)
51.99MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
0.3580USDUpdated Sep 28, 2026Total Debt (MRQ)
18.91MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0727xvs Biotechnology peers
Current Ratio (MRQ)
4.80xvs Biotechnology peers
Book Value per Share (MRQ)
1.79USDUpdated Sep 28, 2026Total Assets
300.91MUSDvs all stocks (USD)
Total Current Assets
65.34MUSDFY2025 · Dec 31, 2025Total Liabilities
33.89MUSDFY2025 · Dec 31, 2025Total Non-current Assets
235.57MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
17.63MUSDFY2025 · Dec 31, 2025Total Current Liabilities
16.25MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
25.52MUSDFY2025 · Dec 31, 2025Other Short-term Investments
28.50MUSDFY2025 · Dec 31, 2025Accounts Receivable
7.39MUSDFY2025 · Dec 31, 2025Accounts Payable
1.88MUSDFY2025 · Dec 31, 2025Short-term Debt
3.88MUSDFY2025 · Dec 31, 2025Deferred Revenue
3.16MUSDFY2025 · Dec 31, 2025Other Current Liabilities
1.22MUSDFY2025 · Dec 31, 2025Long-term Debt
16.45MUSDFY2025 · Dec 31, 2025Other Non-current Liabilities
393.00KUSDFY2025 · Dec 31, 2025Common Stock (Book)
14.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-166.18MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
267.03MUSDvs all stocks (USD)
52-Week Low
1.30USDUpdated Sep 28, 202652-Week High
5.43USDUpdated Sep 28, 202652-Week Change
186.34%vs all stocks
Beta
1.42xvs all stocks
50-Day MA
3.59USDUpdated Sep 28, 2026200-Day MA
2.35USDUpdated Sep 28, 2026Avg 10-Day Volume
1.19MSharesUpdated Sep 28, 2026Avg 30-Day Volume
2.16MSharesUpdated Sep 28, 2026Diluted EPS (TTM)
-0.3600USDUpdated Sep 28, 2026Other Income / Expense
15.00KUSDFY2025 · Dec 31, 20254 interpretations currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsIs this company financially stable?
Diagnostic
Goodwill-Heavy Equity
Equity looks heavy for the industry, but much of it is goodwill from past acquisitions.
Reads
Intangible Concentration
Much of what it owns is goodwill from past deals, large next to its equity.
Reads
Multi-Year Debt Decrease With Cash Near Total Debt And Equity
Long-term debt down in each of four years, and cash now covers most or all of what is left.
Reads
How does this company use capital?
Industry-Benchmarked ROA and Margin Elevated
Returns and margins have sat in the top of its industry across five years.
Reads
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
High gross margins eroded by operating costsNotable
Gross Margin: 0.95Profit Margin: -1.15
Financial Health
Altman Z-Score 10.6: safe zoneNotable
Altman Z-Score: 10.60
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Companies that share the same coordination system — how they create, deliver, or capture value.
Zhejiang Wecome Pharmaceutical Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
XOMA Corporation
Tier 1ProductionApproval-Gated PipelineSenseMakingInterface
Ginkgo Bioworks Holdings Inc.
Tier 1ProductionApproval-Gated PipelineSenseMakingInterface
Shanghai Model Organisms Center Inc.
Tier 1ProductionApproval-Gated PipelineInterfaceSenseMaking
Obio Technology (Shanghai) Corp., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Vireo Growth Inc.
Tier 1ProductionApproval-Gated PipelineFlowInterface
Qurient Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
DNA Link Inc.
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
CHA Biotech Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleInterface
Clarity Pharmaceuticals Ltd
Tier 1ProductionApproval-Gated PipelineRuleSenseMaking
Companies that share active interpretations — structural patterns currently present in both stocks.
Iovance Biotherapeutics, Inc.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity
Suzhou Novoprotein Scientific Co., Ltd.
1 interpretationMulti-Year Debt Decrease With Cash Near Total Debt And Equity